Skip to content

Released Feb 6, 2026, before the open

10-Q filed Feb 6, 2026, 37 days after period end · 0001764013-26-000011

Q3 2026 · 10-Q
Revenue—
Net Income-$110.64MN/M vs Q3 2025N/M vs Q2 2026
EPS Diluted-$0.61N/M vs Q3 2025N/M vs Q2 2026
Operating Cash Flowderived-$92,325,000N/M
Free Cash Flowderived-$92,325,000N/M

What the release said

The release

Same quarter

MetricQ3 2026Q3 2025Q3 2024Q3 2023
Net Income-$110.64M-$111.12M-$51.42M-$63.23M
EPS Diluted-$0.61-$0.76-$0.36-$0.49

The same fiscal quarter, prior years. Thaler holds no estimates to compare against.

Immunovant, Inc. · CIK 1764013 · Engraved from SEC EDGAR